Evan Seigerman
Stock Analyst at BMO Capital
(4.73)
# 685
Out of 4,659 analysts
1055
Total ratings
59.2%
Success rate
10.7%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Initiated Coverage: Buy | $319 | $248.85 | +28.19% | 1 | Aug 18, 2026 | |
| AMGN Amgen | Reiterated: Buy | $450 | $425.28 | +5.81% | 70 | Aug 17, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintained: Hold | $60 | $66.05 | -9.16% | 69 | Aug 17, 2026 | |
| LLY Eli Lilly and Company | Reiterated: Buy | $1,400 | $1,225.73 | +14.22% | 120 | Aug 17, 2026 | |
| GILD Gilead Sciences | Reiterated: Buy | $174 | $143.44 | +21.31% | 80 | Aug 17, 2026 | |
| INCY Incyte | Reiterated: Hold | $130 | $123.47 | +5.29% | 54 | Aug 17, 2026 | |
| MRK Merck & Co. | Reiterated: Buy | $142 | $135.17 | +5.05% | 49 | Aug 17, 2026 | |
| NBIX Neurocrine Biosciences | Maintained: Hold | $190 | $154.23 | +23.19% | 48 | Aug 17, 2026 | |
| NVO Novo Nordisk | Maintained: Hold | $47 | $45.71 | +2.82% | 55 | Aug 17, 2026 | |
| PFE Pfizer | Maintained: Buy | $30 | $27.25 | +10.09% | 56 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $800 | $810.24 | -1.26% | 79 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $600 | $528.19 | +13.60% | 71 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $112 → $178 | $157.34 | +13.13% | 5 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $15.58 | +28.37% | 34 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 | $17.67 | +35.82% | 19 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $11.12 | +34.89% | 12 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $39.00 → $43.00 | $34.25 | +25.55% | 2 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $76 | $54.72 | +38.89% | 10 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $145 | $53.53 | +170.88% | 21 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $128 | $92.75 | +38.01% | 15 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $36 | $30.18 | +19.28% | 10 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $196 → $208 | $212.55 | -2.14% | 63 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 | $11.82 | +69.20% | 1 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $258 → $300 | $258.92 | +15.87% | 27 | Jul 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $6.19 | +126.17% | 9 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $100 | $80.20 | +24.69% | 30 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $35.67 | - | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $9.26 | - | 3 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.18 | n/a | 1 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €114.00 → €129.55 | €136.75 | n/a | 3 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $12.05 | n/a | 5 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $6.96 | n/a | 3 | May 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 → $27 | $5.68 | n/a | 2 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $9 → $15 | $19.95 | n/a | 6 | Dec 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €135.00 → €129.00 | €23.82 | n/a | 6 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $0.69 → $0.84 | $1.21 | n/a | 6 | Aug 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 → $30 | $4.09 | n/a | 4 | May 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $169 → $220 | $27.99 | n/a | 2 | Feb 24, 2020 |
Ascendis Pharma
Aug 18, 2026
Initiated Coverage: Buy
Price Target: $319
Current: $248.85
Upside: +28.19%
Amgen
Aug 17, 2026
Reiterated: Buy
Price Target: $450
Current: $425.28
Upside: +5.81%
Bristol-Myers Squibb Company
Aug 17, 2026
Maintained: Hold
Price Target: $60
Current: $66.05
Upside: -9.16%
Eli Lilly and Company
Aug 17, 2026
Reiterated: Buy
Price Target: $1,400
Current: $1,225.73
Upside: +14.22%
Gilead Sciences
Aug 17, 2026
Reiterated: Buy
Price Target: $174
Current: $143.44
Upside: +21.31%
Incyte
Aug 17, 2026
Reiterated: Hold
Price Target: $130
Current: $123.47
Upside: +5.29%
Merck & Co.
Aug 17, 2026
Reiterated: Buy
Price Target: $142
Current: $135.17
Upside: +5.05%
Neurocrine Biosciences
Aug 17, 2026
Maintained: Hold
Price Target: $190
Current: $154.23
Upside: +23.19%
Novo Nordisk
Aug 17, 2026
Maintained: Hold
Price Target: $47
Current: $45.71
Upside: +2.82%
Pfizer
Aug 17, 2026
Maintained: Buy
Price Target: $30
Current: $27.25
Upside: +10.09%
Aug 17, 2026
Maintained: Buy
Price Target: $800
Current: $810.24
Upside: -1.26%
Aug 17, 2026
Maintained: Buy
Price Target: $600
Current: $528.19
Upside: +13.60%
Aug 17, 2026
Rated: Buy
Price Target: $112 → $178
Current: $157.34
Upside: +13.13%
Aug 17, 2026
Reiterated: Buy
Price Target: $20
Current: $15.58
Upside: +28.37%
Aug 17, 2026
Maintained: Buy
Price Target: $24
Current: $17.67
Upside: +35.82%
Aug 17, 2026
Maintained: Buy
Price Target: $15
Current: $11.12
Upside: +34.89%
Aug 12, 2026
Reiterated: Buy
Price Target: $39.00 → $43.00
Current: $34.25
Upside: +25.55%
Aug 7, 2026
Reiterated: Buy
Price Target: $70 → $76
Current: $54.72
Upside: +38.89%
Aug 6, 2026
Maintained: Buy
Price Target: $145
Current: $53.53
Upside: +170.88%
Aug 5, 2026
Reiterated: Buy
Price Target: $128
Current: $92.75
Upside: +38.01%
Aug 4, 2026
Maintained: Buy
Price Target: $36
Current: $30.18
Upside: +19.28%
Jul 30, 2026
Reiterated: Hold
Price Target: $196 → $208
Current: $212.55
Upside: -2.14%
Jul 27, 2026
Maintained: Buy
Price Target: $20
Current: $11.82
Upside: +69.20%
Jul 13, 2026
Maintained: Buy
Price Target: $258 → $300
Current: $258.92
Upside: +15.87%
Jun 30, 2026
Maintained: Buy
Price Target: $14
Current: $6.19
Upside: +126.17%
Jun 2, 2026
Maintained: Buy
Price Target: $100
Current: $80.20
Upside: +24.69%
Sep 30, 2025
Rated: Hold
Price Target: n/a
Current: $35.67
Upside: -
Sep 30, 2025
Rated: Hold
Price Target: n/a
Current: $9.26
Upside: -
May 6, 2025
Rated: Hold
Price Target: n/a
Current: $4.18
Upside: n/a
Oct 23, 2024
Maintained: Buy
Price Target: €114.00 → €129.55
Current: €136.75
Upside: n/a
Aug 7, 2023
Rated: Hold
Price Target: n/a
Current: $12.05
Upside: n/a
May 9, 2023
Rated: Hold
Price Target: n/a
Current: $6.96
Upside: n/a
Aug 13, 2021
Maintained: Buy
Price Target: $30 → $27
Current: $5.68
Upside: n/a
Dec 16, 2020
Upgraded: Buy
Price Target: $9 → $15
Current: $19.95
Upside: n/a
Oct 16, 2020
Maintained: Hold
Price Target: €135.00 → €129.00
Current: €23.82
Upside: n/a
Aug 13, 2020
Reiterated: Sell
Price Target: $0.69 → $0.84
Current: $1.21
Upside: n/a
May 11, 2020
Reiterated: Buy
Price Target: $13 → $30
Current: $4.09
Upside: n/a
Feb 24, 2020
Maintained: Hold
Price Target: $169 → $220
Current: $27.99
Upside: n/a